Literature DB >> 3936409

Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro.

M T Cushion, D Stanforth, M J Linke, P D Walzer.   

Abstract

Rat Pneumocystis carinii grown on lung-derived cell lines in tissue culture flasks and multiwell plates was tested for susceptibility to four antimicrobial agents currently being used in the treatment of human pneumocystosis. Standard criteria for organism quantitation, replication, viability, and inoculum size were established. Trimethoprim-sulfamethoxazole inhibited P. carinii growth at a concentration ratio of 1:19 microgram/ml, and pentamidine isethionate was active at 0.1 microgram/ml. alpha-Difluoromethylornithine, an inhibitor of polyamine biosynthesis, inhibited P. carinii at a concentration of 1 mM once erythrocytes (which are high in polyamine content) were removed from the inoculum; this effect could be overcome by the polyamine putrescine. Dapsone suppressed P. carinii replication at a dose of 0.1 microgram/ml, but this effect was lost after 72 h in culture. Overall, the reduction in P. carinii numbers with these drugs was relatively modest (45 to 84%), which is consistent with their lack of lethal effects on the organism in vivo. Thus, the system presented here should be helpful in developing new anti-P. carinii agents and in elucidating their mechanism of action.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3936409      PMCID: PMC180331          DOI: 10.1128/AAC.28.6.796

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  33 in total

1.  Delayed development of pneumocystis pneumonia following administration of short-term high-dose trimethoprim-sulfamethoxazole.

Authors:  L J Wolff; R L Baehner
Journal:  Am J Dis Child       Date:  1978-05

2.  Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features.

Authors:  P D Walzer; D P Perl; D J Krogstad; P G Rawson; M G Schultz
Journal:  Ann Intern Med       Date:  1974-01       Impact factor: 25.391

3.  Pentamidine: clinical pharmacologic correlations in man and mice.

Authors:  T P Waalkes; C Denham; V T DeVita
Journal:  Clin Pharmacol Ther       Date:  1970 Jul-Aug       Impact factor: 6.875

4.  Latent Pneumocystis infection of rats, relapse, and chemotherapy.

Authors:  J K Frenkel; J T Good; J A Shultz
Journal:  Lab Invest       Date:  1966-10       Impact factor: 5.662

5.  Combination of pentamidine and trimethoprim-sulfamethoxazole in therapy of Pneumocystis carinii pneumonia in rats.

Authors:  R M Kluge; D M Spaulding; A J Spain
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

6.  Propagation of Pneumocystis carinii in vitro.

Authors:  L L Pifer; W T Hughes; M J Murphy
Journal:  Pediatr Res       Date:  1977-04       Impact factor: 3.756

7.  Serial propagation of Pneumocystis carinii in cell line cultures.

Authors:  C R Latorre; A J Sulzer; L G Norman
Journal:  Appl Environ Microbiol       Date:  1977-05       Impact factor: 4.792

8.  Use of a new bioassay to study pentamidine pharmacokinetics.

Authors:  E M Bernard; H J Donnelly; M P Maher; D Armstrong
Journal:  J Infect Dis       Date:  1985-10       Impact factor: 5.226

9.  Limited effect of trimethoprim-sulfamethoxazole prophylaxis on Pneumocystis carinii.

Authors:  W T Hughes
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

10.  Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis.

Authors:  W T Hughes; P C McNabb; T D Makres; S Feldman
Journal:  Antimicrob Agents Chemother       Date:  1974-03       Impact factor: 5.191

View more
  28 in total

1.  Effect of a bis-benzyl polyamine analogue on Pneumocystis carinii.

Authors:  S Merali; M Saric; K Chin; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

Review 2.  Prevention of infection due to Pneumocystis carinii.

Authors:  J A Fishman
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  In vitro differentiation of human-derived Pneumocystis carinii.

Authors:  W Blumenfeld; J M Griffiss
Journal:  J Clin Microbiol       Date:  1989-03       Impact factor: 5.948

4.  Penetration of dapsone into pulmonary lining fluid of human immunodeficiency virus type 1-infected patients.

Authors:  M Cruciani; G Gatti; C Mengoli; A Cazzadori; L Lazzarini; F Miletich; M S Graziani; M Malena; D Bassetti
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Continuous infusion of DL-alpha-difluoromethylornithine and improved efficacy against a rat model of Pneumocystis carinii pneumonia.

Authors:  K Chin; S Merali; M Sarić; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 6.  Pharmacokinetic optimisation in the treatment of Pneumocystis carinii pneumonia.

Authors:  H F Vöhringer; K Arastéh
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

7.  Levels of dapsone and pyrimethamine in serum during once-weekly dosing for prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis.

Authors:  M Opravil; B Joos; R Lüthy
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

8.  Synergistic combinations of Ro 11-8958 and other dihydrofolate reductase inhibitors with sulfamethoxazole and dapsone for therapy of experimental pneumocystosis.

Authors:  P D Walzer; J Foy; P Steele; M White
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

9.  Polyamine content of Pneumocystis carinii and response to the ornithine decarboxylase inhibitor DL-alpha-difluoromethylornithine.

Authors:  S Merali; A B Clarkson
Journal:  Antimicrob Agents Chemother       Date:  1996-04       Impact factor: 5.191

10.  Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; C K Kim; J Foy; M J Linke; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.